Examining the effects of new insulin cost caps on access and health outcomes
Equity in Insulin Access and Health Outcomes After the Inflation Reduction Act's Out-of-Pocket Spending Caps
This study looks at how the new $35 cap on insulin costs for Medicare patients is helping people with diabetes get the insulin they need and how it affects their health, especially for those from different backgrounds.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11026578 on NIH RePORTER |
What this research studies
This research investigates how the recent cap on out-of-pocket insulin costs affects access to insulin and health outcomes for individuals with diabetes. It focuses on understanding the impact of the Inflation Reduction Act, which limits insulin costs to $35 per month for Medicare beneficiaries. The study aims to measure changes in insulin access, health outcomes, and disparities based on race and income. By analyzing data before and after the policy change, the research seeks to inform future policies that ensure equitable access to insulin for all patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetes who rely on insulin and are affected by the costs associated with their treatment.
Not a fit: Patients who do not use insulin or are not impacted by insulin costs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved access to insulin and better health outcomes for individuals with diabetes, particularly among underserved populations.
How similar studies have performed: Previous research has shown that policy changes aimed at reducing medication costs can significantly improve access and health outcomes, suggesting potential success for this approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Myerson, Rebecca — University of Wisconsin-Madison
- Study coordinator: Myerson, Rebecca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.